ANET vs JNJ: Which Is the Better Buy?
Side-by-side comparison of Arista Networks, Inc. and Johnson & Johnson — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
Arista Networks, Inc. · Technology
$172.86
+82.8% upside to fair value
Grade C
High Quality
VS
Johnson & Johnson · Healthcare
$230.69
+14.0% upside to fair value
Grade C
High Quality
QuantHub Verdict
ANET has more upside to fair value
(+82.8%).
JNJ trades at a lower forward P/E
(26.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ANET |
JNJ |
| Current Price |
$172.86 |
$230.69 |
| Fair Value Estimate |
$316.03 |
$263.05 |
| Upside to Fair Value |
+82.8%
|
+14.0%
|
| Market Cap |
$217.7B |
$555.9B |
| Forward P/E |
61.9x
|
26.8x
|
| EV / EBITDA |
54.9x
|
18.5x
|
| Price / Sales |
24.2x
|
5.8x
|
| Price / FCF |
51.2x
|
28.2x
|
| Revenue Growth YoY |
+28.9%
|
+9.9%
|
| Gross Margin |
64.1%
|
69.1%
|
| Operating Margin |
42.8%
|
26.9%
|
| Return on Equity |
31.0%
|
26.5%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.95%
|
3.54%
|
| Analyst Consensus |
Strong Buy
|
Buy
|
Investment Thesis
Arista Networks is a leading provider of high-speed data center networking hardware and software, specializing in Ethernet switches and cloud networking solutions. The company benefits from strong revenue growth driven by AI and hyperscale cloud demand, with 28.9% revenue growth and 19.3% earnings growth in the most recent quarter. High margins, including a 64.1% gross margin and 42.8% operating …
Johnson & Johnson is a leading healthcare company focused on pharmaceuticals and medical devices following its consumer health spin-off. The business quality is high due to its durable competitive moat, diversified portfolio, and strong management with deep institutional knowledge. Despite a 52.4% decline in earnings in the most recent quarter, revenue grew 9.9% year-over-year in the same period,…
Accumulation Zones
| Metric |
ANET |
JNJ |
| Zone Low |
$237.02 |
$197.29 |
| Zone High |
$268.63 |
$223.59 |
| In Buy Zone? |
Yes
|
No
|